Clinical responses to cytotoxic agents have been largely restricted to the haematological malignancies while the majority of human solid tumours have remained refractory to chemotherapy (Marsoni et al., 1987) . Thus the search for more effective compounds has continued. Chloroethylnitrosoureas are highly active anti-neoplastic agents with a broad spectrum of anti-tumour activity in experimental systems. However, their clinical usefulness has been limited by non-selective host toxicity, particularly myelosuppression.
The chloroethylnitrosoureas decompose spontaneously in aqueous solution to generate reactive intermediates that are capable of alkylating and carbamoylating nucleophilic targets (Cheng et al., 1972) . Alkylation reactions consist of chloroethylations and hydroxyethylations of DNA (Tong et al., 1982) . Chloroethylation of 06-guanine with subsequent cross-link formation is considered to be the most important cytotoxic reaction (Lown et al., 1978) while hydroxyethylation reactions are thought to be responsible for their mutagenic and carcinogenic effects (Pelfrene et al., 1976; Swenson et al., 1979) . Carbamoylating activity is not required for cytotoxicity but does contribute to the overall effect, probably by inhibiting DNA repair (Erickson et al., 1980) and it has been suggested that the carbamoylating activity of some chloroethylnitrosoureas could interfere with the ability of normal cells to recover from the action of these drugs (Sariban et al., 1984) .
In the search for other types of compound that would chloroethylate DNA, a series of 2-haloethylsulphonates was synthesised (Shealy et al., 1983) . 2-Chloroethyl(methylsulphonyl)methanesulphonate (Clomesone) , the most active analogue tested, was shown to be highly effective against P388 leukaemia in vivo (Shealy et al., 1984) . The chemical structure of Clomesone is shown in Figure 1 . Clomesone was further evaluated against a spectrum of animal tumour models and was found to be generally as effective as the chloroethylnitrosoureas (Dykes et al., 1989) .
The results of an investigation of the action of Clomesone in vitro indicated that it affected cellular DNA in a manner similar to the chloroethylnitrosoureas with cross-link formation via chloroethylation of 06-guanine residues (Gibson et al., 1985) . However, it was found to be more specific in its reaction with DNA in that it produced less variety of products than the chloroethylnitrosoureas with no apparent generation of hydroxyethyl adducts (Gibson et al., 1986 (Boyd, 1989) . While in vitro colorimetric assays have the advantage that they can rapidly evaluate novel anti-tumour agents against a large number of cell lines, a recent review of the literature has revealed that marked differences in the response of cells in vitro and tumours in vivo exist (Phillips et al., 1990 (Corbett et al., 1987; .
A series of transplantable murine adenocarcinomas of the colon (MAC tumours) has been shown to exhibit a similar spectrum of histology and chemosensitivity to human large bowel cancer with responses to standard agents only normally seen close to the maximum tolerated dose . It has been used extensively as part of the pre-clinical evaluation of new anti-cancer agents within the Screening and Pharmacology Group of the EORTC (Bibby et al., 1988b) .
The feasibility of performing minimal toxicity studies in conjunction with anti-tumour studies has been described (Bibby et al., 1988b) . Measurement of bone marrow damage, the major dose-limiting toxicity of the chloroethylnitrosoureas, will aid the identification of alternative chloro- ethylating agents with improved therapeutic indices. The assessment of stem cell survival has been recommended to study irreversible cytotoxic bone marrow injury (Schofield, 1986) appropriate concentration for the desired in vivo dose to be administered in 0.1 ml per 10 g body weight by intraperitoneal (ip) or intravenous (iv) injection and for the desired final concentration in vitro to be achieved upon a 1 in 10 dilution.
In vitro studies Cell culture The in vitro activity of Clomesone was assessed against a panel of established tumour cell lines (Phillips et al., 1992) which consisted of three murine colon adenocarcinomas (MAC 1 SA, MAC 16, MAC 26), a murine myelomonocytic leukaemia (WEHI-3B), a human chronic myelogenous leukaemia (K562), a human rectal carcinoma (HRT-18) and four human colon adenocarcinomas (DLD-1, HT-29, HCT-18, HCLO). They were routinely maintained as monolayer cultures, except K562, WEHI-3B and MAC 16 which do not adhere strongly to plastic cultures vessels, in RPMI 1640 tissue culture medium containing sodium pyruvate (1 mM), penicillin/streptomycin (50 IUml I/ 50 pgml-') and supplemented with 10% foetal calf serum.
Chemosensitivity testing In vitro chemosensitivity was assessed using a modified micro-tetrazolium (MTT) assay (Twentyman & Luscombe, 1987) . Cell suspensions were obtained from monolayer cultures in the exponential growth phase and 0.5-1.0 x 104 tumour cells in culture medium were plated into 96-well dishes. Drug solutions were added to give final concentrations ranging from 0.1-100 figml-' at four log increments and the dishes incubated for 4 days at 37°C in an atmosphere of 5% CO2. Prior to the addition of 20 IL MTT (5 mgml-'), 150 IlI old medium was removed and replaced with fresh medium. The dishes were then incubated for a further 4h and the purple formazan crystals produced were dissolved in DMSO. Optical densities of the resulting solutions were read with an ELISA spectrophotometer at a wavelength of 550 nm. Each drug concentration was assayed against each cell line eight times and in four independent experiments. Cytotoxic effects were expressed as percentage survival of treated plates compared to control plates and the initial drug concentration required to inhibit cell survival by 50% (IC50) was obtained from semi-logarithmic plots of cell survival versus concentration.
In vivo studies Animals Pure strain NMRI mice, aged 6-8 weeks, from our inbred colony were used throughout this study. They were fed with a pellet diet (CRM, Labsure, Croydon, England) and water ad libitum.
Tumour system The development of several transplantable adenocarcinomas of the colon in mice from primary tumours induced by prolonged administration of 1,2-dimethylhydrazine has been described elsewhere (1972) . MAC 26 tumour bearers were allocated into groups of 10. The administration of cytotoxic drugs did not commence until these slower growing tumours could be reliably measured (>4 x 4 mm), approximately 17 days after transplantation. Anti-tumour effects against MAC 26 were assessed by twice weekly caliper measurements. Tumour volumes were calculated from the formula a2 x b/2, where a is the smaller diameter and b is the larger (Geran et al., 1972) normalised with respect to the starting volume and semilogarithmic graphs of relative tumour volume against time were plotted. Therapeutic effects were expressed as the regrowth delay which was obtained by comparing the times taken by treated and control tumours to reach a tumour volume ten times that of the starting volume.
Bone marrow toxicity Acute bone marrow toxicity was assessed using a modified version of the spleen colony forming unit assay of Till and McCulloch (1961) . The drugs were administered by a single ip injection to pairs of male mice and bone marrow toxicity was assayed 24h later. Marrow cells were obtained from both femora of each pair of treated mice and pairs of untreated control mice and suspended in RPMI 1640 tissue culture medium. Cell suspensions were diluted so that a 0.2 ml aliquot contained an appropriate number of cells for each experimental group. Cell inocula of 5.0 x 104-7.5 x 105 were initially obtained from the marrows of control mice to investigate the relationship between the number of spleen colonies formed and the number of marrow cells inoculated. Subsequently, a cell inoculum of 1.0 x 105-2.5 x 105 was prepared from both treated and control marrows. The marrow cells were then injected iv via the tail vein into mice which had previously been exposed to irradiation from a Newton Victor Superficial Therapy Unit (GX x 10) at a dose of 11.7 Gy. Groups of six mice were used for each experimental point. After 8 days the mice were killed, the spleens removed and fixed in Bouin's fluid and the nodules on the spleen surface were counted. The survival fraction was determined by comparing the number of colonies observed with the number of colonies expected for a given cell inoculum of untreated marrow cells. (Tables II-IV) . Full dose range data to the point of toxicity were obtained to assure that maximum tolerated doses were achieved for each compound and are presented in Table IV . Activity of Clomesone against each tumour line was reproduced in a separate experiment as was the activity of TCNU and Chlorozotocin against MAC 26. The values obtained for TCNU and Chlorozotocin against MAC 13 and MAC 15A were similar to those in previously reported studies (Bibby et al., 1988a; McElhinney et al., 1989) . Table II shows that Clomesone was active against the ascitic MAC 1 5A tumour at doses of 50 mg kg-' and Table IV . The relative tumour volumes of the group treated with the maximum tolerated dose of 100 mgkg-'ip were not significantly different (P> 0.1) from those of the control group when analysed using the student's t-test. The spleen colony forming unit assay calibration curve is shown in Figure 2 . Linear regression analysis showed a strong positive correlation (r = 0.997) between the number of surface spleen colonies and the number of marrow cells inoculated. Linearity was observed over the range 1.2 x 104-7.4 x I05 cells injected. A cell inoculum below 1.2 x 104 produced no visible surface colonies while a cell inoculum of 3.4 x 106 resulted in the total repopulation of the spleen with no discrete colony formation.
Acute bone marrow toxicity following ip drug administration is described in Table V . The results at the maximum tolerated dose for each drug represent the survival fractions obtained in two independent experiments. Clomesone was less myelosuppressive than TCNU and Chlorozotocin but still produced a 5-fold reduction in colony forming units at the maximum tolerated dose of 100 mgkg -'. The solvent extraction procedure used in the pharmacokinetic studies gave recoveries for six replicate plasma samples, at a concentration of 1 pgml-', of 98.8% for Clomesone and 88.9% for the internal standard, 2-chloroethyl-p-toluenesulphonate with an overall intersample variation for the assay of 9.4%. Adequate separation of Clomesone and the internal standard from plasma interferents was achieved under the assay operating conditions and a typical chromatogram is presented in Figure 3 Number of marrow cells inoculated Figure 2 Spleen colony forming unit assay calibration curve (points are mean ± SD;n = 6). Table I , corresponding to the initial drug concentrations required to achieve a 50% cell kill in vitro ranged from 54->528 ighml-'. (Bibby et al., 1988a) . The development of the selective and sensitive method for the quantitative determination of Clomesone in mouse plasma allowed the pharmacokinetic behaviour of the drug to be characterised with a view to relating the activitytoxicity pattern to bioavailability. The AUC values for Clomesone following a single ip injection of 50 mgkg-, when considered in conjunction with the in vitro c x t product for MAC 26, suggested that the inactivity in vivo was due to ineffective anti-neoplastic drug concentrations at the tumour site. A higher drug exposure of the tumour cells could be achieved in vitro as the drug half-life in tissue culture medium of 3.38h reported in this study was much longer than the previously reported t1/2 of Clomesone in mouse plasma of 0.85h (Chan & Barrientos, 1988) . The dose of 50mgkg-' was chosen as the optimal dose as the higher maximum tolerated dose of 100mgkg-' resulted in no improvement in anti-tumour activity at the expense of increased --V.Z I 1 bone marrow toxicity.
Clomesone was selected for clinical trial on the basis that although it was only as effective as the chloroethylnitrosoureas in some murine tumour models, its chemistry suggested that it would be more toxicologically selective. The broader pre-clinical evaluation performed in this study could find no evidence to support this theory. On the contrary, the findings suggested that the effectiveness of Clomesone, in common with the chloroethylnitrosoureas, would be limited by myelosuppression. Whether the results of this study will be reflected in the clinical setting remains to be seen and the results of the recently completed Phase I clinical trial are awaited with great interest.
